A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of R333 6% Ointment Administered Topically to Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Patients With Active Cutaneous Discoid Lesions

The purpose of this study is to determine the safety, efficacy and tolerability of topical R333 ointment in Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) patients with active discoid lesions.

开始日期2012-08-01

申办/合作机构

Rigel Pharmaceuticals, Inc.

100 项与 R-333 相关的临床结果

登录后查看更多信息

100 项与 R-333 相关的转化医学

登录后查看更多信息

100 项与 R-333 相关的专利（医药）

登录后查看更多信息

项与 R-333 相关的文献（医药）

2020-12-01·Clinical Reviews in Allergy & Immunology2区 · 医学

JAK Inhibitors: Prospects in Connective Tissue Diseases

2区 · 医学

Review

作者: Zhao, Jiuliang ; Li, Jing ; You, Hanxiao ; Zeng, Xiaofeng ; Li, Mengtao ; Wang, Qian ; Tian, Xinping ; Xu, Dong

The dysregulation of the JAK-STAT pathway is associated with various immune disorders. Four JAK inhibitors have been approved for rheumatoid arthritis (RA), and numerous JAK inhibitors are currently being tested in phase II and III trials for the treatment of various autoimmune inflammatory diseases. In this narrative review, we elucidate the involvement of the JAK-STAT signaling pathway in the pathogenesis of connective tissue diseases (CTDs). We also discuss the efficacy of the first- and second-generation JAK inhibitors (tofacitinib, baricitinib, ruxolitinib, peficitinib, filgotinib, upadacitinib, solcitinib, itacitinib, decernotinib, R333, and pf-06651600) for CTDs including RA, systemic lupus erythematosus, dermatomyositis, systemic sclerosis, Sjögren's syndrome, and vasculitis, based on laboratory and clinical research findings. JAK inhibitors have great potential for the treatment of various CTDs by reducing multiple cytokine production and suppressing inflammation, with the advantages of rapid onset in an oral formulation and decreased corticosteroid dependence and the associated adverse events, especially in refractory cases. We also highlight the safety of novel JAK inhibitors, which can cause opportunistic infections, especially viral infections. Being a very recent therapeutic option, information regarding the safety of JAK inhibitors during pregnancy and for pediatric use is limited. However, it is recommended that JAK inhibitors should be avoided in pregnant and breastfeeding women. More clinical data, especially on highly selective inhibitors, are required to judge the efficacy and safety of JAK inhibition in CTDs.

2018-06-01·British Journal of Dermatology

Computerized planimetry to assess clinical responsiveness in a phase II randomized trial of topical R333 for discoid lupus erythematosus

Article

作者: Presto, J.K. ; Werth, V.P. ; Furie, R. ; Okon, L.G. ; Feng, R. ; Fiorentino, D. ; Wallace, D.J.

BACKGROUNDR333 is a topical janus kinase and spleen tyrosine kinase inhibitor being evaluated for discoid lupus erythematosus (DLE) treatment. There is no validated measure to assess the area of active DLE lesions.OBJECTIVESTo evaluate R333 efficacy and assess a technique to measure responsiveness.METHODSFifty-four patients with DLE were randomized in a double-blind design to R333 or placebo. Primary end point was the proportion of patients achieving ≥ 50% decrease in erythema and scale based on lesional Cutaneous Lupus Erythematosus Disease Area and Severity Index^TM for all treated lesions at week 4. Two-dimensional (2D) area measurements for each lesion were recorded at baseline and weeks 1-6. Eighty-eight photographs (44 pre- and 44 post-treatment) were obtained from the trial and change in size of active areas was analysed by computerized planimetry and physician-assessed area change (PAAC).RESULTSThirty-six patients were randomized to R333 and 18 patients were randomized to placebo. Primary end point was not achieved. There was a strong association between lesion activity and physician global assessment (P < 0·001). Photos of 42 patients assessed by computerized planimetry demonstrated excellent inter- and intra-rater reliability. Area change by computerized planimetry showed a strong correlation with PAAC (Spearman r = 0·72). Area change by 2D measurements showed a weak correlation with PAAC (Spearman r = 0·29).CONCLUSIONSFour weeks of R333 treatment did not result in significant improvement in lesion activity. Lesion activity and area change using computerized planimetry are better determinants of responsiveness than area change using 2D measurements.

2011-10-01·The Journal of Immunology2区 · 医学

IL-2 Regulates Expression of C-MAF in Human CD4 T Cells

2区 · 医学

Article

作者: Kanhere, Aditi S. ; Tewolde-Berhan, Lemlem ; Afzali, Behdad ; Kelly, Audrey ; Ragheb, Jack A. ; Cousins, David J. ; Lavender, Paul ; John, Susan ; Pedroza-Pacheco, Isabela ; Rani, Aradhana ; Jenner, Richard G. ; Hackett, Mark ; Jurcevic, Stipo ; Bowen, Holly

AbstractBlockade of IL-2R with humanized anti-CD25 Abs, such as daclizumab, inhibits Th2 responses in human T cells. Recent murine studies have shown that IL-2 also plays a significant role in regulating Th2 cell differentiation by activated STAT5. To explore the role of activated STAT5 in the Th2 differentiation of primary human T cells, we studied the mechanisms underlying IL-2 regulation of C-MAF expression. Chromatin immunoprecipitation studies revealed that IL-2 induced STAT5 binding to specific sites in the C-MAF promoter. These sites corresponded to regions enriched for markers of chromatin architectural features in both resting CD4 and differentiated Th2 cells. Unlike IL-6, IL-2 induced C-MAF expression in CD4 T cells with or without prior TCR stimulation. TCR-induced C-MAF expression was significantly inhibited by treatment with daclizumab or a JAK3 inhibitor, R333. Furthermore, IL-2 and IL-6 synergistically induced C-MAF expression in TCR-activated T cells, suggesting functional cooperation between these cytokines. Finally, both TCR-induced early IL4 mRNA expression and IL-4 cytokine expression in differentiated Th2 cells were significantly inhibited by IL-2R blockade. Thus, our findings demonstrate the importance of IL-2 in Th2 differentiation in human T cells and support the notion that IL-2R–directed therapies may have utility in the treatment of allergic disorders.

100 项与 R-333 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
盘状红斑狼疮	临床2期	美国	Rigel Pharmaceuticals, Inc.	2012-08-01
盘状红斑狼疮	临床2期	加拿大	Rigel Pharmaceuticals, Inc.	2012-08-01
结节性湿疹	临床2期	加拿大	Rigel Pharmaceuticals, Inc.	2012-08-01
结节性湿疹	临床2期	美国	Rigel Pharmaceuticals, Inc.	2012-08-01
系统性红斑狼疮	临床2期	美国	Rigel Pharmaceuticals, Inc.	2012-08-01
系统性红斑狼疮	临床2期	加拿大	Rigel Pharmaceuticals, Inc.	2012-08-01
接种疫苗	临床2期	美国	Rigel Pharmaceuticals, Inc.	2012-08-01
接种疫苗	临床2期	加拿大	Rigel Pharmaceuticals, Inc.	2012-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01597050 (SKINDLE, CTgov)	临床2期	结节性湿疹 \| 系统性红斑狼疮 \| 接种疫苗 \| 盘状红斑狼疮	54	R932333 (Drug: R932333)	網衊糧顧壓糧鑰廠廠鏇(繭範窪選鏇蓋窪網蓋膚) = 遞網範製襯範顧廠製選選積鬱餘蓋壓憲願醖構 (製選艱壓網壓鏇餘製簾, 糧鏇憲壓範築艱衊鹹製 ~ 鹽積蓋觸襯艱餘餘蓋齋) 更多	-	2016-06-08
				Placebo (Placebo)	網衊糧顧壓糧鑰廠廠鏇(繭範窪選鏇蓋窪網蓋膚) = 網醖範衊廠艱顧壓醖艱選積鬱餘蓋壓憲願醖構 (製選艱壓網壓鏇餘製簾, 遞鏇顧憲獵艱淵衊遞廠 ~ 淵蓋艱觸網醖遞網構餘) 更多